A significant finding from the niacin glioblastoma trial underscores the potential clinical impact of NAD+ metabolism restoration in cancer immunotherapy. Trial participants receiving high-dose vitamin B3 demonstrated progression-free survival rates substantially exceeding historical control data, which typically range from 6 to 9 months with standard chemoradiation therapy. The improved outcomes suggest that restoring NAD+ metabolism—depleted by glioblastoma tumours as an immune evasion mechanism—may represent a viable therapeutic pathway. This mechanism works by reactivating T-cell function that the tumour environment actively suppresses. Researchers caution that these are preliminary findings requiring validation in larger patient populations before definitive efficacy can be established. Read the full article on GMJ Newsroom.
Was this article helpful?
